Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas.
作者信息
Assi Tarek, Le Cesne Axel
机构信息
Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, France.
Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
出版信息
Future Oncol. 2025 Apr;21(8):879-882. doi: 10.1080/14796694.2025.2463881. Epub 2025 Feb 7.
Abstract
摘要
相似文献
1
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomas.
Future Oncol. 2025 Apr;21(8):879-882. doi: 10.1080/14796694.2025.2463881. Epub 2025 Feb 7.
2
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Lancet Oncol. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.
3
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Crit Rev Oncol Hematol. 2016 Feb;98:73-80. doi: 10.1016/j.critrevonc.2015.10.020. Epub 2015 Nov 3.
4
Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
Drug Des Devel Ther. 2015 Oct 27;9:5785-91. doi: 10.2147/DDDT.S92395. eCollection 2015.
5
Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials.
Oncologist. 2017 Dec;22(12):1518-1527. doi: 10.1634/theoncologist.2016-0474. Epub 2017 Aug 23.
6
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
J Cancer Res Clin Oncol. 1991;117 Suppl 4(Suppl 4):S193-7. doi: 10.1007/BF01613226.
7
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Health Technol Assess. 2015 Jan;19(7):1-480. doi: 10.3310/hta19070.
8
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Oncol Res. 2013;20(10):483-90. doi: 10.3727/096504013x13685487925130.
9
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Future Oncol. 2015;11(11 Suppl):15-24. doi: 10.2217/fon.15.76.
10
Liposarcoma of Maxilla- A Rare Case Report.
Indian J Otolaryngol Head Neck Surg. 2024 Dec;76(6):5978-5982. doi: 10.1007/s12070-024-05022-x. Epub 2024 Sep 11.
本文引用的文献
1
Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394.
2
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.
3
Maintenance therapy and drug holiday in sarcoma patients: systematic review.
Acta Oncol. 2020 Sep;59(9):1084-1090. doi: 10.1080/0284186X.2020.1759825. Epub 2020 May 13.
4
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4.
5
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
Cancer Treat Rev. 2019 Jan;72:37-44. doi: 10.1016/j.ctrv.2018.11.003. Epub 2018 Nov 15.
7
Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.
Cancer Treat Rev. 2018 Feb;63:71-78. doi: 10.1016/j.ctrv.2017.12.003. Epub 2017 Dec 6.
8
Soft Tissue and Uterine Leiomyosarcoma.
J Clin Oncol. 2018 Jan 10;36(2):144-150. doi: 10.1200/JCO.2017.75.9845. Epub 2017 Dec 8.
9
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.
10
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23.
Zotero 插件